Actively Recruiting
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Led by Qurient Co., Ltd. · Updated on 2025-08-17
130
Participants Needed
11
Research Sites
208 weeks
Total Duration
On this page
Sponsors
Q
Qurient Co., Ltd.
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
CONDITIONS
Official Title
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer
- Disease measurable by RECIST v 1.1 criteria
- ECOG performance status of 0, 1, or 2
- Life expectancy of at least 3 months
- Signed, written informed consent approved by an IRB
You will not qualify if you...
- New York Heart Association Class III or IV cardiac disease
- Myocardial infarction, severe unstable angina, coronary or peripheral artery bypass graft, or congestive heart failure within the past 6 months
- Corrected QT interval (QTcF) greater than 470 msec for females and greater than 450 msec for males
- Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
- Active, poorly controlled autoimmune or inflammatory diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Mayo Clinic
Phoenix, Arizona, United States, 85054
Actively Recruiting
2
University of Southern California
Los Angeles, California, United States, 90033
Actively Recruiting
3
Mayo Clinic
Jacksonville, Florida, United States, 32224
Actively Recruiting
4
Northwestern University
Chicago, Illinois, United States, 60611
Actively Recruiting
5
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
6
Atlantic Health System Hospital
Morristown, New Jersey, United States, 07960
Actively Recruiting
7
Mary Crowley Cancer Research
Dallas, Texas, United States, 75230
Actively Recruiting
8
National Cancer Center
Goyang-si, South Korea
Actively Recruiting
9
CHA University Bundang Medical Center
Seongnam-si, South Korea
Actively Recruiting
10
Asan Medical Center
Seoul, South Korea
Not Yet Recruiting
11
Severance Hospital
Seoul, South Korea
Not Yet Recruiting
Research Team
Q
Qurient Clinical Trial Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here